Turnover: 123.7 million EUR (2023)
Country: Italy
Established in 1929 as Beaufour Laboratories, IPSEN's (Institute for Synthetic Products and Natural Extraction) business has historically benefited from natural plant-based drugs, as evidenced by the success of Romarene, a digestive disorder drug with extracts of rosemary, since the group's creation.
IPSEN groups drug production in the "family health" segment, which accounts for 16 percent of the group's business. In addition to these cutting-edge therapeutic activities illustrated by research partnerships with the CNRS and MIT, IPSEN specializes in France in the gastroenterology and cognitive disorders markets. In particular, it has been the originator of SMECTA and sole distributor of Dysport since 1994.
IPSEN has historically focused on Anglo-Saxon markets. Its flagship product is SMEBIOCTA, a plant-based solution for regulating gut flora.
The company is headed by David Meek.
News
Ipsen's commitment to the area of rare diseases 29/02/2024
Performance and strategies of the biopharmaceutical company Ipsen in 2023: 1. **Increase in sales:** In 2023, Ipsen recorded an increase in global sales of 3.4% over the previous year. 2. **Operating margin:** The company recorded an operating margin of 26.1%, which shows an increase of 2% compared to 2022. 3. **Growth factors:** Growth was supported by the company's historical assets, new drugs, pipeline expansion, and accelerated investment in research and development, particularly benefited by recent acquisitions focused on the area of rare diseases. 4. **Entry into the rare disease area:** In 2023, Ipsen acquired Albireo, a leading developer of bile acid modulators for the treatment of pediatric and adult cholestatic liver disease, bringing odevixibat, the first approved treatment against progressive familial intrahepatic cholestasis (Pfic), to the market. 5. **Future Plans:** By 2024, Ipsen plans to launch four innovative therapies worldwide and expand its pipeline, supported by an external innovation strategy in its three core therapeutic areas. 6. **Rare disease commitment:** With new developments such as odevixibat and an evolving pipeline, Ipsen marks its official entry into the rare disease field, aiming to bring therapeutic innovations that can change the course of disease, with a focus on drugs with novel mechanisms of action.
Botox: botulinum toxin boosts pharma's bottom line 02/08/2023
- The United States accounts for half of the global botulinum toxin market.
- Last year, Botox accounted for $5.2 billion in worldwide sales for AbbVie, with equal shares between aesthetics (+21% excluding currency effect) and therapeutics (+13%).
- In the United States, Dysport (Ipsen) has only 5% of the therapeutic market, compared with 30% in France.
- In aesthetics in the US, Ipsen has an estimated share of between 20% and 25%.
- Of the French laboratory Ipsen's half-year sales of 1.5 billion euros (+7%), 319 million (+32%) come from botulinum toxin sold in therapeutics and, in some countries, in aesthetics.
- Botox holds 40% to 50% of the therapeutic market in France, compared with 30% for Ipsen.
Ipsen exceeds its targets, helped by its Botox competitor 11/02/2023
- Family-owned laboratory controlled by descendants of Henri Beaufour
- Ipsen exceeds its targets
- Strong growth in sales of Dysport, its botulinum toxin competitor to Botox, generating €594 million in sales
Ipsen bets $1 billion on a biotech to treat liver disease 21/01/2023
- Ipsen announces largest acquisition since the sale of Smecta (its family healthcare division) in 2022
- french pharmaceutical group to launch $952 million takeover bid for US biotech Albireo
- By 2021, Ipsen has added 16 new molecules to its portfolio
Ipsen strengthens its position in the dynamic rare diseases segment 09/01/2023
- Ipsen to pay €1 billion for US biotech Albireo
- The market for rare diseases is close to $150 billion
Financial Data
DUNS: 308197185
Legal Name: IPSEN PHARMA
Address: 65 QUAI GEORGES GORSE , 92100 BOULOGNE-BILLANCOURT
Number of employees: Entre 500 et 999 salariés (2020)
Capital: 7 755 053 EUR
Financial Data:
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Turnover | 1 635 000 000 | 1 567 000 000 | 1 536 600 000 | 1 340 000 000 | 1 206 000 000 | 1 084 567 984 | 1 038 847 015 |
| Gross margin (€) | 1 303 900 000 | 1 270 800 000 | 1 158 400 000 | 1 087 500 000 | 945 100 000 | 808 112 464 | - |
| EBITDA (€) | 400 700 000 | 464 400 000 | 320 900 000 | 212 200 000 | 172 500 000 | 183 046 982 | - |
| Operating profit (€) | 306 500 000 | 338 200 000 | 244 500 000 | 144 000 000 | 112 400 000 | 155 291 033 | - |
| Net profit (€) | 96 000 000 | 222 000 000 | 345 200 000 | 127 000 000 | 233 000 000 | 178 518 785 | 185 808 126 |
| Turnover growth rate (%) | 4,3 | 2,1 | 14,7 | 11 | 11,3 | 4,4 | - |
| Ebitda margin rate (%) | 24,5 | 29,6 | 20,9 | 15,8 | 14,3 | 16,9 | - |
| Operating margin rate (%) | 18,7 | 21,6 | 15,9 | 10,7 | 9,3 | 14,3 | - |
| Working Capital (turnover days) | -217,5 | -229,3 | -88,2 | -62 | -67 | -144,5 | - |
| Working Capital requirements (turnover days) | 29,4 | 44,9 | 35,8 | 18,1 | 16 | 35,8 | - |
| Net margin (%) | 5,9 | 14,2 | 22,5 | 9,5 | 19,3 | 16,5 | - |
| Added value / Turnover (%) | 31,1 | 35,6 | 28,4 | 17,6 | 18,4 | 21,4 | - |
| Wages and social charges (€) | 122 900 000 | 111 300 000 | 107 600 000 | 141 600 000 | 136 300 000 | 127 177 208 | - |
| Salaries / Turnover (%) | 7,5 | 7,1 | 7 | 10,6 | 11,3 | 11,7 | - |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Président | David | LOEW | 57 | |
| Directeur général | François-Maurice | GARNIER | 62 | |
| Directeur général | Aidan | MURPHY | 58 | |
| Directeur général | Stéphane | ANDRE | 66 | |
| Directeur général | Stéphane | SIMON | 55 | |
| Directeur général | Régis | MULOT | 58 | |
| Directeur général | Henri | GUENARD | 44 | |
| Directeur général | Aymeric | LE CHATELIER | 55 | |
| Directeur général | Patrice | ZAGAME | 64 | |
| Directeur général | Bartosz, Daniel | BEDNARZ | 54 | |
| Directeur général | Philippe | DE SORBIER DE POUGNADORESSE | 52 | |
| Directeur général | Howard | MAYER | 62 |
Studies mentioning this company
The herbal medicine market - France
Other companies mentioned:
- Arkopharma
- Bayer
- Ipsen
- Santé Verte
- Merck KGaA
- Nutreov Physcience
- PiLeJe
- Fenioux Groupe
- NaturHouse
- Puressentiel France
- Pranarôm (Inula Groupe)
- Naturactive (Pierre Fabre)
- Olisma
- Densmore (Havea Groupe)
- Herbalife
- Institut Endobiogénie
- Atlantic Nature
- Olisma
The aesthetic medicine market - United Kingdom
Other companies mentioned:
- Allergan plc (Abbvie)
- Ipsen
- Merz Pharmaceuticals
- Cynosure
- Alma Lasers
The aesthetic medicine market - Italy
Other companies mentioned:
- Fidia Farmaceutici
- Decomedical
- ITS Group
- BTL
- EME Estetica
- Ipsen
- Merz Pharmaceuticals
- Allergan plc (Abbvie)
The aesthetic medicine market - France
Other companies mentioned:
- Allergan plc (Abbvie)
- Galderma
- Merz Pharmaceuticals
- La Roche-Posay
- Filorga Cosmétiques (Colgate Palmolive)
- Lierac (Laboratoire Native)
- Laboratoires Sebbin
- Arion
- Candela Medical
- Deleo
- Ipsen
- Clinique des Champs Elysées
- Lazeo
- Maison Lutetia
- Skincareagency
- Healshape